Newsroom

February 25, 2020

First Prospective Study Shows +RNAinsight™ Identifies More Patients with Increased Risk for Hereditary Cancer Than DNA-Only Testing

The first notable improvement in diagnostic yield for high-risk cancer genes in more than 10 years, +RNAinsight adds RNA genetic testing to DNA multigene panels (Aliso Viejo, CA) February 25, 2020: Ambry Genetics (Ambry), a leading clinical genetic testing lab, announced the publication of a ...


Read More

January 28, 2020

Invicro Scientists Work on Imaging Synaptic Density in Schizophrenia Published in Nature Communications

BOSTON, MA, 28 January 2020 – Invicro LLC, a Konica Minolta company announces that the paper “Synaptic Density Marker SV2A is Reduced in Schizophrenia Patients and Unaffected by Antipsychotics in Rats1” has been published in Nature Communications. Invicro is a global provider of imaging biomarkers, ...


Read More

January 14, 2020

Invicro and Paige Partner to Offer Comprehensive Tissue Biomarker Profiling Services

(BOSTON, MA and NEW YORK, NY) January 14, 2020 — Invicro LLC, a Konica Minolta Company and Paige, Inc., the leader in computational pathology, today announced a strategic alliance to provide integrated pathology solutions to support Pharmaceutical and Biotechnology sponsors with their drug discovery ...


Read More

December 23, 2019

Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and Dr. Jack Hoppin is Named President of Konica Minolta Precision Medicine

(BOSTON, MA) December 23, 2019 — Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective ...


Read More

December 16, 2019

Ambry Genetics Receives New York State Approval to Offer Paired RNA and DNA Genetic Testing for Hereditary Cancer Risk

+RNAinsight™ is now available for New York patients, and will help identify thousands more patients at increased risk for cancer (Aliso Viejo, CA) December 16, 2019: Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today that the New York State Clinical Laboratory ...


Read More

December 10, 2019

New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone

Separate data demonstrated that finding mutations that increase risks for breast cancer frequently led clinicians to change their medical recommendations to patients. (Aliso Viejo, CA) December 10, 2019: Researchers at Ambry Genetics (Ambry), a leading clinical genetic testing lab, will announce ...


Read More

December 04, 2019

Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care

Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer IRVING, Texas and ALISO VIEJO, Calif., December 4, 2019 – Caris Life Sciences®, a leading innovator ...


Read More

November 05, 2019

New Data from Ambry Genetics Show Substantial Increase in Diagnostic Yield, Further Supporting the Routine Use of RNA Genetic Testing for Hereditary Cancer Panels

Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing. Results from a separate study demonstrated that genetic testing results frequently lead to changes in patient care ...


Read More

October 23, 2019

Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides More Accurate, Actionable Results for Patients who Receive DNA Testing for Hereditary Cancer Risk

A new study published in JAMA Network Open demonstrates that RNA genetic testing can substantially improve the interpretation of DNA testing results and improve medical care (Aliso Viejo, CA) October 23, 2019: Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication ...


Read More

October 15, 2019

New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results. Separate data showed RNA genetic testing’s ability to clarify the interpretation of complex ...


Read More
Back 1 of 3 Next